Clinical Trials

24 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

61 enrolled

Tumor-Agnostic

Neoplasms

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

76 enrolled

Advanced Solid Tumours

NCT03238027 2024-05-17

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

45 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03610061 2024-04-12

RaDD

34 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

29 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

72 enrolled 23 charts

Solid Tumor

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

15 enrolled

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

20 enrolled

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

15 enrolled

Breast

Breast Neoplasms

NCT02503774 2023-07-11

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

192 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03889275 2023-02-21

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Advanced Solid Tumors

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

BreastGastrointestinalGenitourinaryGynecologic

104 enrolled 23 charts

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03773666 2022-09-13

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

12 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04261075 2022-08-15

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

57 enrolled

Advanced Solid Tumors

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02777710 2021-09-05

MEDIPLEX

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

26 enrolled

Advanced Malignancy

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

85 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT02900157 2021-01-14

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

42 enrolled

Advanced Solid Tumors

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

3 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03430518 2020-08-05

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

9 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Advanced Solid Tumors

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

380 enrolled

Advanced Solid Tumors

NCT03005002 2019-12-26

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

9 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

459 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

11 enrolled

Advanced Solid Malignancies

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT02221960 2019-03-13

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Recurrence

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Other solid neoplasmThoracic

65 enrolled

Part A and B: Advanced Solid Malignancies

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

2 enrolled

Small Cell Lung Carcinoma

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer